Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
GLUT1 recalibrates T cells through perturbing redox-balance
FY 2023-24
Summary
The dynamic tumour microenvironment is one of the greatest challenges towards achieving complete tumour eradication by immunotherapy in aggressive, treatment-resistant cancers. While adoptive T cell therapy holds promise as a curative treatment against solid childhood malignancies, T cells struggle to maintain their killing capacity once they reach the tumour itself. Tumours are difficult to infiltrate, and once inside, T cells encounter an environment deficient in their primary fuel sources: glucose and amino acids. To improve immunotherapy, then, we must learn how to make cytotoxic (CD8+) T cells hardier when faced with nutrient stress. As such, my project focuses on Glut1, a glucose transporter expressed on the surface of CD8+ T cells. Previous data from our laboratory has demonstrated Glut1’s importance in achieving tumour clearance in mice, accompanied with shifting the T cell to a more oxidized metabolic state. To better understand the relationship between Glut1 expression and the oxidation state in the cell, I will be using Glut1-deficient mouse CD8+ T cells to assess redox-related intermediates and redox shuttle pathways through targeted metabolomics. I will define the directionality of the relationship between changes in Glut1 expression and oxidation state in the cell through forcing redox changes by treating T cells with oxidizers or anti-oxidants, both of which are used in experimental cancer treatments. Finally, follow-up studies in a pre-clinical model of neuroblastoma will validate our work for further application in clinical settings. What we learn from this project will inform how we approach immunotherapy treatment design for children affected by cancer.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
506564
Name
Yao Qi
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
GLUT1 recalibrates T cells through perturbing redox-balance
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adoptive Cell Therapy; Car T Cells; Cellular Metabolism; Cellular Therapy; Glucose Metabolism; Immunotherapy; Metabolic Reprogramming; Metabolomics; Redox Homeostasis; T Cells
Abstract
The dynamic tumour microenvironment is one of the greatest challenges towards achieving complete tumour eradication by immunotherapy in aggressive, treatment-resistant cancers. While adoptive T cell therapy holds promise as a curative treatment against solid childhood malignancies, T cells struggle to maintain their killing capacity once they reach the tumour itself. Tumours are difficult to infiltrate, and once inside, T cells encounter an environment deficient in their primary fuel sources: glucose and amino acids. To improve immunotherapy, then, we must learn how to make cytotoxic (CD8+) T cells hardier when faced with nutrient stress. As such, my project focuses on Glut1, a glucose transporter expressed on the surface of CD8+ T cells. Previous data from our laboratory has demonstrated Glut1’s importance in achieving tumour clearance in mice, accompanied with shifting the T cell to a more oxidized metabolic state. To better understand the relationship between Glut1 expression and the oxidation state in the cell, I will be using Glut1-deficient mouse CD8+ T cells to assess redox-related intermediates and redox shuttle pathways through targeted metabolomics. I will define the directionality of the relationship between changes in Glut1 expression and oxidation state in the cell through forcing redox changes by treating T cells with oxidizers or anti-oxidants, both of which are used in experimental cancer treatments. Finally, follow-up studies in a pre-clinical model of neuroblastoma will validate our work for further application in clinical settings. What we learn from this project will inform how we approach immunotherapy treatment design for children affected by cancer.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Yao, Qi
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~